Radiotherapy after radical prostatectomy: Immediate or early delayed?

Strahlentherapie und Onkologie

Volumn 188, Issue 12, 2012, Pages 1096-1101

  Bottke, D ^a   Bartkowiak, D ^a   Schrader, M ^a   Wiegel, T ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Adjuvant radiotherapy; Progression free survival; Prostate cancer; Radical prostatectomy; Salvage radiotherapy

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; HORMONAL THERAPY; HUMAN; OVERALL SURVIVAL; PELVIS LYMPH NODE; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; TUMOR INVASION; ADJUVANT THERAPY; BLOOD; CANCER GRADING; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; MALE; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRACTICE GUIDELINE; PROSTATE TUMOR; RADIOTHERAPY; TIME TO TREATMENT; TUMOR RECURRENCE;

COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; LYMPHATIC IRRADIATION; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; TIME-TO-TREATMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84872849399     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0234-9     Document Type: Article

References (66)

1. Anscher MS, Clough R, Dodge R (2000) Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 48:369-375
2. Begg CB, Riedel ER, Bach PB et al (2002) Variations in morbidity after radical prostatectomy. N Engl J Med 346:1138-1144
3. Bernard JR Jr, Buskirk SJ, Heckman MG et al (2010) Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys 76:735-740
4. Bolla M, Reijke TM de, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516-2527
5. Bolla M, Poppel H van, Collette L et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572-578
6. Bolla M, Van Poppel H, Tombal B et al (2010) 10-year Results of Adjuvant Radiotherapy after Radical Prostatectomy in pT3N0 Prostate Cancer (EORTC 22911). Int J Radiat Oncol Biol Phys 78:S 29
7. Bottke D, Abrahamsson PA, Welte B et al (2007) Adjuvant radiotherapy after radical prostatectomy. EJC (Suppl) 5:171-176
8. Briganti A, Karnes RJ, Pozzo LF et al (2011) Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+prostate cancer: results of a matched analysis. Eur Urol 59:832-840
9. Budiharto T, Perneel C, Haustermans K et al (2010) A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. Radiother Oncol 97:474-479
10. Buskirk SJ, Pisansky TM, Schild SE et al (2006) Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 176:985-990
11. Cadeddu JA, Partin AW, DeWeese TL et al (1998) Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 159:173-177, (discussion 7-8)
12. Choo R, Danjoux C, Gardner S et al (2009) Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Int J Radiat Oncol Biol Phys 75:983-989
13. Chun FK, Graefen M, Zacharias M et al (2006) Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J Urol 24:273-280
14. Cimitan M, Bortolus R, Morassut S, et al (2006) [18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33:1387-1398
15. Coen JJ, Zietman AL, Thakral H et al (2002) Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 20:3199-3205
16. Connolly JA, Shinohara K, Presti JC Jr et al (1996) Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47:225-231
17. Da Pozzo LF, Cozzarini C, Briganti A et al (2009) Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 55:1003-1111
18. Deliveliotis C, Manousakas T, Chrisofos M et al (2007) Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. World J Urol 25:309-313
19. Do T, Parker RG, Do C et al (1998) Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am 4:324-330
20. Garg MK, Tekyi-Mensah S, Bolton S et al (1998) Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 51:998-1002
21. Hagan M, Zlotecki R, Medina C et al (2004) Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 59:329-340
22. Hanlon AL, Horwitz EM, Hanks GE et al (2004) Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 58:43-52
23. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61-71
24. Horwitz EM, Bae K, Hanks GE et al (2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26:2497-2504
25. Kaminski JM, Hanlon AL, Joon DL et al (2003) Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys 57:24-28
26. King CR, Kapp DS (2008) Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 71:346-350
27. Loeb S, Roehl KA, Viprakasit DP et al (2008) Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. Eur Urol 54:88-94
28. Michalski JM, Lawton C, El Naqa I et al (2010) Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy fpr prostate cancer. Int J Radiat Oncol Biol Phys 76:361-368
29. Miralbell R, Vees H, Lozano J et al (2007) Endorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys 67:356-361
30. Neuhof D, Hentschel T, Bischof M et al (2007) Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys 67:1411-1417
31. Ost P, De Troyer B, Fonteyne V et al (2011) A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 80:1316-1322
32. Parker C, Sydes MR, Catton C et al (2007) Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 99:1376-1379
33. Pazona JF, Han M, Hawkins SA et al (2005) Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 174:1282-1286
34. Picchio M, Briganti A, Fanti S et al (2011) The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 59:51-60
35. Pinto F, Prayer-Galetti T, Gardiman M et al (2006) Clinical and pathological characteristics of patients presenting with biochemical progression after radical retropubic prostatectomy for pathologically organ-confined prostate cancer. Urol Int 76:202-208
36. Pisansky TM, Kozelsky TF, Myers RP et al (2000) Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 163:845-850
37. Poortmans P, Bossi A, Vandeputte K et al (2007) Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 84:121-127
38. Rinnab L, Mottaghy FM, Blumstein NM et al (2007) Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100:786-793
39. Roehl KA, Han M, Ramos CG et al (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172:910-914
40. Roscigno M, Cozzarini C, Scattoni V et al (2007) A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy. Radiother Oncol 82:30-37
41. Rossi CJ Jr, Joe Hsu IC, Abdel-Wahab M et al (2011) ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancer. Am J Clin Oncol 34:92-98
42. Salomon L, Anastasiadis AG, Antiphon P et al (2003) Prognostic consequences of the location of positive surgical margins in organ-confined prostate cancer. Urol Int 70:291-296
43. Scattoni V, Picchio M, Suardi N et al (2007) Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 52:423-429
44. Scattoni V, Roscigno M, Raber M et al (2003) Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 44:407-414
45. Sella T, Schwartz LH, Swindle PW et al (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379-385
46. Shekarriz B, Upadhyay J, Wood DP Jr et al (1999) Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology 54:1044-1048
47. Shipley WU, Hunt D, Lukka H et al (2010) Initial Report of RTOG 9601: a phase III trial in prostate cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) improves freedom from progression and reduces the incidence of metastatic disease in patients following Radical Prostatectomy (RP) with pT2-3, N0 disease, and elevated PSA levels. Int J Radiat Oncol Biol Phys 78:S 27
48. Siegmann A, Bottke D, Faehndrich J et al (2012) Salvage radiotherapy after prostatectomy-What is the best time to treat? Radiother Oncol: 103:239-243
49. Siegmann A, Bottke D, Faehndrich J et al (2011) Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. Strahlenther Onkol 187:467-472
50. Soto DE, Passarelli MN, Daignault S et al (2011) Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients. Int J Radiat Oncol Biol Phys
51. Spiotto MT, Hancock SL, King CR (2007) Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 69:54-61
52. Stamey TA, Yang N, Hay AR et al (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916
53. Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035-2041
54. Stephenson AJ, Shariat SF, Zelefsky MJ et al (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291:1325-1332
55. Stephenson AJ, Wood DP, Kattan MW et al (2009) Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol 182:1357-1263
56. Swindle P, Eastham JA, Ohori M et al (2005) Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 174:903-907
57. Thompson IM Jr, Tangen CM, Paradelo J et al (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296:2329-2335
58. Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956-962
59. Trabulsi EJ, Valicenti RK, Hanlon AL et al (2008) A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 72:1298-1302, (discussion 302-304)
60. Trock BJ, Han M, Freedland SJ et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760-2769
61. Tsien C, Griffith KA, Sandler HM et al (2003) Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. Urology 62:93-98
62. Van der Kwast TH, Bolla M, Van Poppel H et al (2007) Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25:4178-4186
63. Ward JF, Zincke H, Bergstralh EJ et al (2004) Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172:2244-2248
64. Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924-2930
65. Wiegel T, Lohm G, Bottke D et al (2009) Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome-results of a retrospective study. Int J Radiat Oncol Biol Phys 73:1009-1016
66. Wiltshire KL, Brock KK, Haider MA et al (2007) Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys 69:1090-1099